Cambridge Cognition Holdings PLC - Cambridge, England-based neuroscience technology - Wins GBP1.3 million contract as the cognitive assessment partner for a schizophrenia trial, marking the fourth one secured with the company's particular pharmaceutical client in seven months.
Revenue from the contract is expected to be booked over the next three years.
"Schizophrenia affects more than 20 million people worldwide and we are pleased to be strengthening our relationship with a company that recognises the importance of sensitive and accurate cognitive assessment in developing effective therapeutics for the disorder. This quick succession of unusually large contracts with the same pharmaceutical company is a testament to the excellent customer experience and high-quality products Cambridge Cognition delivers," notes Chief Executive Officer Matthew Stork.
Current stock price: 92.70 pence, up 9.1% on Tuesday
Year-to-date change: up 38%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Cambridge Cog (COG)